Concepts (204)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| AIDS Dementia Complex | 18 | 2015 | 107 | 3.870 |
Why?
|
| Cognition Disorders | 9 | 2017 | 233 | 1.810 |
Why?
|
| HIV Infections | 14 | 2023 | 2207 | 1.720 |
Why?
|
| HIV Seropositivity | 8 | 2018 | 182 | 1.240 |
Why?
|
| Receptor, Insulin | 2 | 2015 | 22 | 0.950 |
Why?
|
| HIV-1 | 9 | 2020 | 678 | 0.810 |
Why?
|
| Antiretroviral Therapy, Highly Active | 5 | 2023 | 219 | 0.710 |
Why?
|
| Puerto Rico | 10 | 2020 | 1352 | 0.680 |
Why?
|
| Blood-Brain Barrier | 2 | 2018 | 153 | 0.620 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2018 | 224 | 0.600 |
Why?
|
| Access to Information | 1 | 2015 | 13 | 0.560 |
Why?
|
| Humans | 39 | 2023 | 34853 | 0.540 |
Why?
|
| Periodicals as Topic | 1 | 2015 | 48 | 0.530 |
Why?
|
| Exercise | 1 | 2020 | 524 | 0.530 |
Why?
|
| Models, Biological | 1 | 2018 | 642 | 0.520 |
Why?
|
| Cell Movement | 1 | 2018 | 545 | 0.520 |
Why?
|
| Adult | 23 | 2020 | 11034 | 0.510 |
Why?
|
| Female | 28 | 2020 | 19873 | 0.470 |
Why?
|
| Macrophages | 5 | 2017 | 431 | 0.470 |
Why?
|
| Insulin Resistance | 1 | 2015 | 177 | 0.450 |
Why?
|
| Apolipoproteins | 1 | 2012 | 19 | 0.440 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2012 | 18 | 0.430 |
Why?
|
| DNA, Viral | 1 | 2013 | 295 | 0.430 |
Why?
|
| Anti-Retroviral Agents | 1 | 2012 | 139 | 0.410 |
Why?
|
| Learning | 1 | 2012 | 108 | 0.410 |
Why?
|
| HIV | 2 | 2013 | 97 | 0.400 |
Why?
|
| Proteomics | 6 | 2017 | 302 | 0.390 |
Why?
|
| Middle Aged | 17 | 2020 | 9642 | 0.380 |
Why?
|
| Basilar Artery | 1 | 2010 | 10 | 0.380 |
Why?
|
| Puerperal Disorders | 1 | 2010 | 6 | 0.380 |
Why?
|
| Education, Medical, Graduate | 1 | 2010 | 53 | 0.370 |
Why?
|
| Education, Distance | 1 | 2010 | 40 | 0.360 |
Why?
|
| Neuropsychological Tests | 7 | 2013 | 255 | 0.360 |
Why?
|
| Cognition | 2 | 2012 | 373 | 0.360 |
Why?
|
| Thrombosis | 1 | 2010 | 61 | 0.360 |
Why?
|
| Dementia | 1 | 2010 | 133 | 0.350 |
Why?
|
| Monocytes | 6 | 2013 | 258 | 0.340 |
Why?
|
| Research | 1 | 2007 | 159 | 0.280 |
Why?
|
| Protein Array Analysis | 2 | 2004 | 26 | 0.260 |
Why?
|
| Hippocampus | 2 | 2022 | 546 | 0.260 |
Why?
|
| Memory | 3 | 2012 | 165 | 0.240 |
Why?
|
| Neurology | 2 | 2013 | 12 | 0.230 |
Why?
|
| Proteome | 2 | 2017 | 132 | 0.230 |
Why?
|
| Flumazenil | 1 | 2000 | 1 | 0.200 |
Why?
|
| Midazolam | 1 | 2000 | 3 | 0.200 |
Why?
|
| Cohort Studies | 5 | 2017 | 1422 | 0.200 |
Why?
|
| Smoking | 1 | 2007 | 903 | 0.200 |
Why?
|
| Hypnotics and Sedatives | 1 | 2000 | 27 | 0.200 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 1 | 2020 | 18 | 0.190 |
Why?
|
| HIV Antibodies | 1 | 2020 | 29 | 0.190 |
Why?
|
| Glycopeptides | 1 | 2020 | 11 | 0.190 |
Why?
|
| Oxygen Consumption | 1 | 2020 | 98 | 0.190 |
Why?
|
| Anthropometry | 1 | 2020 | 91 | 0.180 |
Why?
|
| Electroencephalography | 1 | 2000 | 108 | 0.180 |
Why?
|
| Cells, Cultured | 3 | 2018 | 1442 | 0.180 |
Why?
|
| Disease Progression | 3 | 2013 | 580 | 0.180 |
Why?
|
| Cross-Sectional Studies | 4 | 2017 | 2561 | 0.180 |
Why?
|
| Longitudinal Studies | 5 | 2013 | 841 | 0.180 |
Why?
|
| Retrospective Studies | 3 | 2015 | 1961 | 0.170 |
Why?
|
| Quality of Life | 2 | 2013 | 459 | 0.170 |
Why?
|
| Cerebrospinal Fluid | 2 | 2007 | 18 | 0.160 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2017 | 9 | 0.150 |
Why?
|
| Resilience, Psychological | 1 | 2017 | 61 | 0.140 |
Why?
|
| Biomedical Research | 2 | 2018 | 371 | 0.140 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2017 | 243 | 0.140 |
Why?
|
| Reproducibility of Results | 4 | 2017 | 901 | 0.140 |
Why?
|
| Infant, Newborn | 1 | 2018 | 871 | 0.140 |
Why?
|
| Databases, Factual | 2 | 2017 | 288 | 0.130 |
Why?
|
| Lymphocytes | 2 | 2013 | 116 | 0.130 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2015 | 23 | 0.130 |
Why?
|
| Public Health | 1 | 2018 | 348 | 0.130 |
Why?
|
| Viral Load | 4 | 2013 | 300 | 0.130 |
Why?
|
| Behavioral Symptoms | 1 | 2013 | 6 | 0.120 |
Why?
|
| Lipid Metabolism Disorders | 1 | 2013 | 3 | 0.120 |
Why?
|
| Sampling Studies | 1 | 2013 | 60 | 0.120 |
Why?
|
| 14-3-3 Proteins | 1 | 2013 | 19 | 0.120 |
Why?
|
| Epilepsy | 1 | 2013 | 41 | 0.120 |
Why?
|
| Fatigue | 1 | 2013 | 79 | 0.120 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 445 | 0.120 |
Why?
|
| Cystatin B | 1 | 2013 | 8 | 0.120 |
Why?
|
| Drug Monitoring | 1 | 2012 | 17 | 0.110 |
Why?
|
| Cathepsin B | 1 | 2013 | 29 | 0.110 |
Why?
|
| Gene Expression | 2 | 2013 | 639 | 0.110 |
Why?
|
| Male | 8 | 2017 | 18870 | 0.110 |
Why?
|
| Internet | 2 | 2012 | 204 | 0.110 |
Why?
|
| Reaction Time | 1 | 2012 | 130 | 0.110 |
Why?
|
| HIV Seronegativity | 2 | 2013 | 38 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 187 | 0.100 |
Why?
|
| Nervous System Diseases | 1 | 2012 | 66 | 0.100 |
Why?
|
| Alleles | 1 | 2012 | 284 | 0.100 |
Why?
|
| Psychometrics | 2 | 2017 | 292 | 0.100 |
Why?
|
| Pharmacology | 1 | 2010 | 5 | 0.100 |
Why?
|
| Thrombophilia | 1 | 2010 | 3 | 0.090 |
Why?
|
| Allergy and Immunology | 1 | 2010 | 11 | 0.090 |
Why?
|
| Foramen Ovale, Patent | 1 | 2010 | 5 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 528 | 0.090 |
Why?
|
| Neurosciences | 1 | 2010 | 23 | 0.090 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 608 | 0.090 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2007 | 185 | 0.090 |
Why?
|
| Case-Control Studies | 1 | 2012 | 1056 | 0.090 |
Why?
|
| Mentors | 1 | 2010 | 111 | 0.090 |
Why?
|
| Phosphorylation | 1 | 2012 | 878 | 0.090 |
Why?
|
| Antioxidants | 2 | 2010 | 386 | 0.090 |
Why?
|
| Focus Groups | 1 | 2010 | 307 | 0.090 |
Why?
|
| Health Status | 1 | 2012 | 356 | 0.090 |
Why?
|
| Language | 1 | 2010 | 143 | 0.090 |
Why?
|
| Catalase | 1 | 2008 | 106 | 0.080 |
Why?
|
| Glutathione Peroxidase | 1 | 2008 | 109 | 0.080 |
Why?
|
| Intelligence Tests | 1 | 2007 | 5 | 0.080 |
Why?
|
| Superoxide Dismutase | 1 | 2008 | 149 | 0.080 |
Why?
|
| Aged, 80 and over | 2 | 2013 | 2333 | 0.080 |
Why?
|
| ROC Curve | 1 | 2007 | 138 | 0.080 |
Why?
|
| Academies and Institutes | 1 | 2007 | 35 | 0.080 |
Why?
|
| Hawaii | 1 | 2013 | 1878 | 0.080 |
Why?
|
| Women's Health | 1 | 2007 | 135 | 0.070 |
Why?
|
| Wechsler Scales | 1 | 2006 | 7 | 0.070 |
Why?
|
| Psychomotor Performance | 1 | 2007 | 126 | 0.070 |
Why?
|
| Aged | 3 | 2013 | 6448 | 0.070 |
Why?
|
| Minority Groups | 1 | 2010 | 537 | 0.070 |
Why?
|
| Algorithms | 1 | 2007 | 435 | 0.060 |
Why?
|
| Gene Expression Profiling | 1 | 2007 | 600 | 0.060 |
Why?
|
| Prospective Studies | 1 | 2007 | 1353 | 0.060 |
Why?
|
| Cyclohexanes | 1 | 2023 | 29 | 0.060 |
Why?
|
| Heroin | 1 | 2002 | 11 | 0.060 |
Why?
|
| Narcotics | 1 | 2002 | 28 | 0.060 |
Why?
|
| Triazoles | 1 | 2023 | 85 | 0.060 |
Why?
|
| Analysis of Variance | 2 | 2017 | 528 | 0.050 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2002 | 75 | 0.050 |
Why?
|
| Prevalence | 1 | 2006 | 1425 | 0.050 |
Why?
|
| Depression | 1 | 2007 | 664 | 0.050 |
Why?
|
| Blotting, Western | 2 | 2017 | 834 | 0.050 |
Why?
|
| Neuroprotective Agents | 1 | 2003 | 231 | 0.050 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2020 | 20 | 0.050 |
Why?
|
| Cricetulus | 1 | 2020 | 74 | 0.050 |
Why?
|
| CHO Cells | 1 | 2020 | 107 | 0.050 |
Why?
|
| Glycosylation | 1 | 2020 | 92 | 0.050 |
Why?
|
| Cricetinae | 1 | 2020 | 217 | 0.050 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2020 | 100 | 0.050 |
Why?
|
| Antibodies, Neutralizing | 1 | 2020 | 102 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2020 | 485 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2020 | 252 | 0.040 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 2 | 2007 | 79 | 0.040 |
Why?
|
| Microwaves | 1 | 2017 | 26 | 0.040 |
Why?
|
| Insurance, Major Medical | 1 | 2017 | 5 | 0.040 |
Why?
|
| Magnetics | 1 | 2017 | 36 | 0.040 |
Why?
|
| Young Adult | 2 | 2020 | 4012 | 0.040 |
Why?
|
| Adolescent | 2 | 2013 | 5035 | 0.040 |
Why?
|
| Chromatography, Liquid | 1 | 2017 | 140 | 0.040 |
Why?
|
| Mass Spectrometry | 2 | 2007 | 255 | 0.040 |
Why?
|
| Calgranulin B | 1 | 2015 | 4 | 0.040 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2017 | 173 | 0.030 |
Why?
|
| Disease Outbreaks | 1 | 2017 | 155 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2017 | 231 | 0.030 |
Why?
|
| Substance-Related Disorders | 1 | 2002 | 685 | 0.030 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2015 | 88 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 2007 | 1490 | 0.030 |
Why?
|
| Incidence | 1 | 2017 | 882 | 0.030 |
Why?
|
| Hospitalization | 1 | 2017 | 370 | 0.030 |
Why?
|
| Sphingolipids | 1 | 2013 | 13 | 0.030 |
Why?
|
| Homozygote | 1 | 2013 | 75 | 0.030 |
Why?
|
| Heterozygote | 1 | 2013 | 91 | 0.030 |
Why?
|
| Ceramides | 1 | 2013 | 41 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2013 | 165 | 0.030 |
Why?
|
| Outpatients | 1 | 2012 | 33 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 424 | 0.030 |
Why?
|
| Cholesterol | 1 | 2013 | 194 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2013 | 392 | 0.030 |
Why?
|
| Immunologic Techniques | 1 | 2010 | 10 | 0.020 |
Why?
|
| Peroxiredoxins | 1 | 2010 | 10 | 0.020 |
Why?
|
| Chromatography, Affinity | 1 | 2010 | 64 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2013 | 490 | 0.020 |
Why?
|
| Peroxidase | 1 | 2010 | 50 | 0.020 |
Why?
|
| Free Radical Scavengers | 1 | 2010 | 65 | 0.020 |
Why?
|
| Thioredoxins | 1 | 2010 | 43 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2008 | 151 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2008 | 160 | 0.020 |
Why?
|
| Complement C3 | 1 | 2007 | 15 | 0.020 |
Why?
|
| Animals | 2 | 2020 | 14307 | 0.020 |
Why?
|
| Receptors, CCR5 | 1 | 2007 | 59 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2007 | 195 | 0.020 |
Why?
|
| Receptors, CXCR4 | 1 | 2007 | 67 | 0.020 |
Why?
|
| Glioma | 1 | 2007 | 76 | 0.020 |
Why?
|
| Fluorescent Dyes | 1 | 2007 | 173 | 0.020 |
Why?
|
| Virulence | 1 | 2007 | 221 | 0.020 |
Why?
|
| Transfection | 1 | 2007 | 496 | 0.020 |
Why?
|
| Neurons | 2 | 2003 | 1130 | 0.020 |
Why?
|
| Virus Replication | 1 | 2007 | 261 | 0.020 |
Why?
|
| Risk Factors | 1 | 2013 | 3414 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2007 | 1124 | 0.020 |
Why?
|
| Phenotype | 1 | 2007 | 650 | 0.020 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2003 | 6 | 0.020 |
Why?
|
| Subtraction Technique | 1 | 2003 | 7 | 0.010 |
Why?
|
| Nerve Growth Factors | 1 | 2003 | 33 | 0.010 |
Why?
|
| United States | 1 | 2013 | 3894 | 0.010 |
Why?
|
| Gene Products, tat | 1 | 2002 | 34 | 0.010 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 1 | 2002 | 52 | 0.010 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 2002 | 54 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2003 | 555 | 0.010 |
Why?
|
| Dopamine | 1 | 2002 | 232 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2007 | 2128 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2003 | 562 | 0.010 |
Why?
|
| Anti-HIV Agents | 1 | 2003 | 394 | 0.010 |
Why?
|
| Brain | 1 | 2003 | 1268 | 0.010 |
Why?
|
| Rats | 1 | 2002 | 3261 | 0.010 |
Why?
|